Bernadette Broccolo and Michael Peregrine wrote this bylined article on how efforts by healthcare sector stakeholders to help commercialize biomedical advances create “a clear need for enhanced board engagement and oversight of these initiatives.” The authors explained that these well-intentioned efforts “do not relieve or insulate board members from the fiduciary duty diligently to oversee the assessment and management of the relative benefits and risks” in such investment decisions.
